EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Recursion Pharmaceuticals's Enterprise Value is $1,465.94 Mil.
Recursion Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-332.03 Mil. Therefore, Recursion Pharmaceuticals's EV-to-EBIT for today is -4.42.
The historical rank and industry rank for Recursion Pharmaceuticals's EV-to-EBIT or its related term are showing as below:
RXRX'
s EV-to-EBIT Range Over the Past 10 Years
Min: -55.94 Med: -5.4 Max: -1.84
Current: -4.42
During the past 5 years, the highest EV-to-EBIT of Recursion Pharmaceuticals was -1.84. The lowest was -55.94. And the median was -5.40.
RXRX's EV-to-EBIT is ranked worse than 100% of 444
companies
in the Biotechnology industry
Industry Median: 8.185
vs RXRX: -4.42
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Recursion Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 was $1,964.47 Mil.
Recursion Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-332.03 Mil. Recursion Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -16.90%.
Recursion Pharmaceuticals EV-to-EBIT Historical Data
The historical data trend for Recursion Pharmaceuticals's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Recursion Pharmaceuticals's EV-to-EBIT
For the Biotechnology subindustry, Recursion Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Recursion Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Recursion Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Recursion Pharmaceuticals's EV-to-EBIT falls into.
Recursion Pharmaceuticals EV-to-EBIT Calculation
Recursion Pharmaceuticals's EV-to-EBIT for today is calculated as:
Recursion Pharmaceuticals's current Enterprise Value is $1,465.94 Mil.
Recursion Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-332.03 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Recursion Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 was $1,964.47 Mil.
Recursion Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-332.03 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Recursion Pharmaceuticals EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Recursion Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Recursion Pharmaceuticals (Recursion Pharmaceuticals) Business Description
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RXRX has been successfully added to your 